Johnson & Johnson closes acqusition of Abiomed
By Scott Kanowsky Investing.com -- Amgen Inc. (NASDAQ:AMGN) has agreed to buy Horizon Therapeutics PLC (NASDAQ:HZNP) in an all-cash deal that values the biotech firm at about...
By Sarina Isaacs, Reuters Investing.com - Here are the hottest pieces of M&A news from the past week, as covered first on InvestingPro+. Pan American Silver (NASDAQ:PAAS) Corp....
Last August, a little section of U.S. President Joe Biden’s much-touted Inflation Reduction Act caught the attention of investors. It introduced a 1% tax on stock...
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking...
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro-heart pump with an integrated motor and sensors, and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro-heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; the Impella SmartAssist platform, which includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staff; and the OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in Germany, France, the United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts with additional offices in Halethorpe, Maryaland, Aachen, and Berlin, Germany, and Tokyo, Japan. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.